Menin Inhibitors in Leukemia: Module

CME

Menin Inhibition in Acute MLL Rearranged Leukemias: A New Target for Precision Care

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: October 17, 2022

Expiration: October 16, 2023

Eytan M. Stein
Eytan M. Stein, MD

Activity

Progress
1
Course Completed

References

  1. Döhner H, Wei A, Appelbaum F, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;Epub ahead of print.
  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: acute myeloid leukemia. V.2.2022. nccn.org. Accessed September 21, 2022.
  3. Falini B, Martelli M, Bolli N, et al. Acute myeloid leukemia with nutated nucleophosmin (NPM1): Is it a distinct entity? Blood. 2011;117:1109-1120.
  4. Issa G, Ravandi F, DiNardo C, et al. Therapeutic implications of menin inhibition in acute leukemias. Leukemia. 2021;35:2482-2495.
  5. Swaminathan M, Gourgeois W, Armstrong S, et al. Menin inhibitors in acute myeloid leukemia—what does the future hold? Cancer Journal. 2022;28:62-66.
  6. Borkin D, He S, Miao H, et al. Pharmacologic inhibition of the menin-MLL interaction blocks progression of MLL leukemia in vivo. Cancer Cell. 2015;27:589-602.
  7. Uckelmann HJ, Kim SM, Wong EM, et al. Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia. Science. 2020;367:586-590.
  8. Kühn M, Armstrong SA. Designed to kill: novel menin-MLL inhibitors target MLL-rearranged leukemia. Cancer Cell. 2015;27:431-433.
  9. Stein E, Aldoss I, DiPersio J, et al. Safety and efficacy of menin inhibition in patients with MLL-rearranged and NPM1 mutant acute leukemia: a phase 1, first-in-human study of SNDX-5613. Presented at: 63rd Annual Meeting of the American Society of Hematology; December 11-14, 2021. Abstract 699.
  10. Wang ES, Altman J, Pettit K, et al. Preliminary data report on a phase 1/2A first in human study of the menin-KMT2A (MLL) inhibitor KO-539 in patients with relapsed or refractory acute myeloid leukemia. Presented at: 62nd Annual Meeting of the American Society of Hematology; December 5-8, 2020. Abstract 115.
  11. Dzama MM, Steiner M, Rausch J, et al. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition. Blood. 2020;136:2442-2456.